Bisphosphonate therapy for fibrous dysplasia

Pediatric Endocrinology Reviews

Volumn 4, Issue SUPPL. 4, 2007, Pages 440-445

  DiMeglio, Linda A ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Alendronate; Diphosphonates; Pain; Pamidronate alkaline phosphatase; Review; Zolendronic acid

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ALBRIGHT SYNDROME; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CLINICAL FEATURE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; FIBROUS DYSPLASIA; HORMONE ACTION; HUMAN; HYPOPHOSPHATEMIA; NONHUMAN; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FIBROUS DYSPLASIA OF BONE; FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS;

EID: 35148876609     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Freidman E, Spiegel MA. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-1695
2. Shenker A, Weinstein LS, Sweet DE, Spiegel AM. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994;79(3):750-755
3. Shenker A, Chanson P, Weinstein LS, Chi P, Spiegel AM, Lomri A, Marie PJ. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet 1995;4(9):1675-1676
4. Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey PG. Mutations of the GNAS1 gene, stromal cell dysfunction and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 2000;15(1):120-128
5. Candeliere GA, Glorieux FH, Prud'homme J, St Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 1995;332(23):1546-1551
6. Yoneda T, Nakai M, Moriyama K, Scott L, Ida N, Kunitomo T, Mundy GR. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res 1993;53(4):737-740
7. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996;98(1):30-35
8. Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, Bianco P. Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res 2003;18(7):1235-1246
9. Coley BL. Neoplasms of bone and related conditions. 2nd ed. New York Paul Hoeber Inc 1960
10. Albright F, Butler AM, Hamstra AJ, Smith R. Syndrome characterized by osteitis fibrosis disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. New Eng J Med 1937;216:727-746
11. Feuillan PP, Jones J, Cutler GB, Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993;77(3):647-651
12. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 2005;20(2):219-226
13. Ozaki T, Sugihara M, Nakatsuka Y, Kawai A, Inoue H. Polyostotic fibrous dysplasia. A long-term follow up of 8 patients. Int Orthop 1996;20(4):227-232
14. DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation and treatment. J Bone Joint Surg Am 2005;87(8):1848-1864
15. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-388
16. Allgrove J. Bisphosphonates. Arch Dis Child 1997;76:73-575
17. Rizzoli R, Fleisch H, Bonjour J-P. Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest 1977;60:639
18. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-2333
19. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 2001;16(5):806-813
20. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous Pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004;35(1):235-242
21. Hannon TS, Noonan K, Steinmetz R, Eugster EA, Levine MA, Pescovitz OH. Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone? J Pediatr 2003;142(5):532-538
22. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000;13(Suppl 6):1439-1455
23. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994;131(3):229-234
24. Di Candia S, Weber G, Mora S, de Pellegrin M, Chiumello G. Early fractures and occult hyperthyroidism: McCune-Albright syndrome? Horm Res 2001;56(1-2):58-62
25. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27(2):465-483
26. Hjelmstedt A, Ljunghall S. A case of Albright's syndrome treated with calcitonin. Acta Orthop Scand 1979;50(3):251-253
27. Long A, Loughlin T, Towers RP, McKenna TJ. Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin: aetiological and therapeutic implications. Ir J Med Sci 1988;157(7):229-234
28. Grant DB, Savage MO, Russell R. McCune Albright syndrome with severe progressive polyostotic fibrous dysplasia: Failure of experimental treatment with salmon calcitonin and dichloro-Diphosphonate. 21st annual meeting European Society for Pediatric Endocrinology. Abstract 72. Pediatric Research 1982;16:899
29. Cole DE, Fraser FC, Glorieux FH, Jequier S, Marie PJ, Reade TM, Scriver CR. Panostotic fibrous dysplasia: a congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia and hypophosphatemia. Am J Med Genet 1983;14(4):725-735
30. Liens D., Delmas P.D., Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. Lancet 1994;343(8903):953-954
31. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997;12(10):1746-1752
32. Weinstein RS. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 1997;12(8):1314-1315
33. Pfeilschifter J, Ziegler R. (Effect of Pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome). Med Klin (Munich) 1998;93(6):352-359
34. Devogelaer JP. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 2000;12(4):331-335
35. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000;89(2):188-193
36. Lane JM, Khan SN, O'Connor WJ, Nydick M, Hommen JP, Schneider R, Tomin E, Brand J, Curtin J. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 2001;(382):6-12
37. Parisi MS, Oliveri MB, Mautalen CA. Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densitom 2001;4(2):167-172
38. Isaia GC, Lala R, Defilippi C, Matarazzo P andreo M, Roggia C, Priolo G, de Sanctis C. Bone turnover in children and adolescents with McCune-Albright syndrome treated with Pamidronate for bone fibrous dysplasia. Calcif Tissue Int 2002;71(2):121-128
39. Matarazzo P, Lala R, Masi G andreo M, Altare F, de Sanctis C. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002;15(Suppl 3):929-937
40. Yamamoto T, Ozono K, Shima M, Yoshikawa H, Okada S. Alendronate and pharmacological doses of 1alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia. J Bone Miner Metab 2002;20(3):170-173
41. Parisi MS, Oliveri B, Mautalen CA. Effect of intravenous Pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 2003;33(4):582-588
42. Lala R, Matarazzo P andreo M, Marzari D, Bellone J, Corrias A, de Sanctis C. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006;19 (Suppl 2):583-593
43. Zacharin M, O'Sullivan M. Intravenous Pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000;137(3):403-409
44. O'Sullivan M, Zacharin M. Intramedullary rodding and bisphosphonate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. J Pediatr Orthop 2002;22(2):255-260
45. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of Pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003;88(10):4569-4575
46. Chan B, Zacharin M. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. J Pediatr Endocrinol Metab 2006;19(1):75-80
47. Glorieux FH, Rauch F. Medical therapy of children with fibrous dysplasia. J Bone Miner Res 2006;21 (Suppl 2):110-113
48. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 2004;19(4):571-577
49. Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 2001;69(2):94-101
50. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999;60(2):68-73
51. Chan B, Zacharin M. Maternal and infant outcome after Pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006;91(6):2017-2020
52. Riminucci M, Saggio I, Gehron RP, Bianco P. Fibrous dysplasia as a stem cell disease. J Bone Miner Res 2006;21 Suppl 2:125-131
53. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 2006;21(Suppl 2):114-119